BIO Submits Comments to the Centers for Medicare and Medicaid Services (CMS) Regarding the Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces

February 25, 2013

 

 

Marilyn Tavenner, B.S.N., M.H.A.

Administrator

Centers for Medicare & Medicaid Services

Room 445–G, Hubert H. Humphrey Building

200 Independence Avenue, SW

Washington, DC 20201

 

Re: Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces

 

Dear Ms. Tavenner:

 

          The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft letter related to the Patient Protection and Affordable Care Act’s (ACA) health insurance Marketplaces that the Centers for Medicare & Medicaid Services (CMS) issued on February 4, 2014, entitled “Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces” (the “Draft Letter”).[1]

 

          BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced health care expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.



[1] Center for Consumer Information and Insurance Oversight (CCIIO), Centers for Medicare & Medicaid Services (CMS), Draft 2015 Letter to Issuers in the Federally-facilitated Marketplaces (FFM) (Feb. 4, 2014). Available at: http://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/draft-issuer-letter-2-4-2014.pdf (hereinafter “Draft Letter to Issuers”). 

 

To view the full comment letter, click here.